This is an edited version of an article written by Kristie L. Kahl and published in OncLive Sept. 9, 2022
Maintenance olaparib (Lynparza) plus bevacizumab (Avastin) following first-line standard-of-care treatment improved overall survival (OS) in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency (HRD), according to final OS results from the phase 3 PAOLA-1/ENGOT-ov25 ... trial presented at the 2022 ESMO Congress.
“These data confirm the addition of olaparib to bevacizumab as a standard of care for HRD-positive patients in this setting and the importance of precision medicine and biomarker testing to guide treatment decisions,” Isabelle L. Ray-Coquard, MD, PhD, a medical oncologist at Centre Léon Berard Université Claude Bernard in Lyon, France, said during a presentation of the data....
No comments:
Post a Comment